AbbVie Inc (ABBV)

Add to Watchlists
Create an Alert
Quickflows
105.92 +0.27  +0.26% NYSE Mar 5, 08:48 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All ABBV News

News

View All Events

Events

Date Type Description
04/30/2021 Earnings AbbVie Inc First Quarter Earnings Results for 2021
04/30/2021 Misc AbbVie Inc First Quarter Earnings Conference Call for 2021
04/14/2021 Dividends Amount: 1.30, Declared Date: Feb 18 2021, Pay Date: May 14 2021
02/03/2021 Earnings AbbVie Inc Fourth Quarter Earnings Result for 2020
02/03/2021 08:00 CST Misc AbbVie Inc Fourth Quarter Earnings Conference Call for 2020
01/14/2021 Dividends Amount: 1.30, Declared Date: Oct 30 2020, Pay Date: Feb 16 2021
10/30/2020 Earnings AbbVie Inc Third Quarter Earnings Result for 2020
10/30/2020 08:00 CDT Misc AbbVie Inc Third Quarter Earnings Conference Call for 2020
10/14/2020 Dividends Amount: 1.18, Declared Date: Sep 11 2020, Pay Date: Nov 16 2020
07/31/2020 08:00 CDT Misc AbbVie Inc Second Quarter Earnings Conference Call for 2020
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 45.80B
Total Expenses (TTM) 33.24B
Net Income (TTM) 4.616B

Balance Sheet View Statement

Total Assets (Quarterly) 150.56B
Total Liabilities (Quarterly) 137.47B
Shareholders Equity (Quarterly) 13.08B

Cash Flow Statement View Statement

Cash from Operations (TTM) 17.59B
Cash from Investing (TTM) -37.56B
Cash from Financing (TTM) -11.50B

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.abbvie.com
  • Investor Relations URL: http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-IRHome
  • HQ State/Province: Illinois
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Apr. 30, 2021
  • Last Earnings Release: Feb. 03, 2021
  • Next Ex-Dividend Date: Apr. 14, 2021
  • Last Ex-Dividend Date: Jan. 14, 2021
  • Description: AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 105.92
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FIJYX Fidelity Advisor® Biotechnology Z 23.64%
FBIOX Fidelity® Select Biotechnology 8.06%
XLV Health Care Select Sector SPDR® ETF 4.48%
VHT Vanguard Health Care ETF 3.35%
QUAL iShares MSCI USA Quality Factor ETF 2.22%
CIRFX American Funds Capital Income Bldr 529F 1.90%
VHYAX Vanguard High Dividend Yield Index Adm 1.64%
VYM Vanguard High Dividend Yield ETF 1.64%
CMLFX American Funds American Mutual 529F 1.50%
VTV Vanguard Value ETF 1.31%
VIVAX Vanguard Value Index Inv 1.27%
IWF iShares Russell 1000 Growth ETF 0.98%

Comparables

Edit
JNJ Johnson & Johnson
LLY Eli Lilly and Co
MRK Merck & Co Inc
PFE Pfizer Inc
BMY Bristol-Myers Squibb Co

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.